These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31231828)

  • 21. Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study).
    Nakasone H; Terasako-Saito K; Hirano T; Wake A; Shimizu S; Kurita N; Yamazaki E; Usuki K; Akazawa K; Kanda J; Minauchi K; Yamamoto G; Tanimoto S; Kamoshita M; Yokoyama Y; Miyaoka E; Ota S; Kako S; Izutsu K; Kanda Y
    Hematol Oncol; 2018 Feb; 36(1):202-209. PubMed ID: 28681529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates.
    Terpos E; Kastritis E; Ntanasis-Stathopoulos I; Christoulas D; Papatheodorou A; Eleutherakis-Papaiakovou E; Kanellias N; Fotiou D; Ziogas DC; Migkou M; Roussou M; Trougakos IP; Gavriatopoulou M; Dimopoulos MA
    Am J Hematol; 2019 Apr; 94(4):400-407. PubMed ID: 30592079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
    Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
    Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre.
    Hock BD; Mulholland KS; Ganly P; McKenzie JL; Pearson JF; MacPherson SA
    Intern Med J; 2019 May; 49(5):598-606. PubMed ID: 30411451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
    Einsele H; Engelhardt M; Tapprich C; Müller J; Liebisch P; Langer C; Kropff M; Mügge LO; Jung W; Wolf HH; Metzner B; Hart C; Gramatzki M; Hertenstein B; Pfreundschuh M; Rösler W; Fischer T; Maschmeyer G; Kanz L; Hess G; Jäger E; Bentz M; Dürk HA; Salwender H; Hebart H; Straka C; Knop S
    Br J Haematol; 2017 Nov; 179(4):586-597. PubMed ID: 28961309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
    Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
    Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents.
    Su B; Zhu X; Jiang Y; Wang L; Zhao N; Ran X; Zheng X; Guo H
    Leuk Lymphoma; 2019 Jun; 60(6):1381-1388. PubMed ID: 30516074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
    Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
    Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
    Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
    Ho PJ; Moore EM; McQuilten ZK; Wellard C; Bergin K; Augustson B; Blacklock H; Harrison SJ; Horvath N; King T; Mollee P; Quach H; Reid C; Rosengarten B; Walker P; Wood EM; Spencer A
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e415-e424. PubMed ID: 31208889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma.
    Barta SK; Jain R; Mazumder A; Carter J; Almanzar L; Browne R; Shahnaz S; Elkind R; Kaminetzky D; Battini R; Derman O; Kornblum N; Verma A; Braunschweig I
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):650-657. PubMed ID: 28684379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation.
    Gao W; Li J; Jian Y; Yang G; Wu Y; Li Y; Len Y; Liu A; Tian Y; Wang H; Zhou H; Zhang Z; Chen W
    Int J Hematol; 2019 Feb; 109(2):169-174. PubMed ID: 30311142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
    Goldschmidt H; Baertsch MA; Schlenzka J; Becker N; Habermehl C; Hielscher T; Raab MS; Hillengass J; Sauer S; Müller-Tidow C; Luntz S; Jauch A; Hose D; Seckinger A; Brossart P; Goerner M; Klein S; Schmidt-Hieber M; Reimer P; Graeven U; Fenk R; Haenel M; Martin H; Lindemann HW; Scheid C; Nogai A; Salwender H; Noppeney R; Besemer B; Weisel K;
    Leukemia; 2021 Apr; 35(4):1134-1144. PubMed ID: 32694619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma.
    Blanes M; González JD; Lahuerta JJ; Ribas P; Lorenzo I; Boluda B; Sanz MA; de la Rubia J
    Leuk Lymphoma; 2015 Feb; 56(2):415-9. PubMed ID: 24828869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance.
    Cohen YC; Joffe E; Benyamini N; Dimopoulos MA; Terpos E; Trestman S; Held-Kuznetsov V; Avivi I; Kastritis E
    Leuk Lymphoma; 2016; 57(6):1382-8. PubMed ID: 26727104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.
    Parrish C; Morris CTCM; Williams CD; Cairns DA; Cavenagh J; Snowden JA; Ashcroft J; Cavet J; Hunter H; Bird JM; Chalmers A; Brown JM; Yong K; Schey S; Chown S; Cook G;
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1009-1016. PubMed ID: 26827659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.